TMA2018CDF-2363

 

 Project title: Clinical application of whole genome sequencing in multidrug resistance tuberculosis patients in Tanzania

Funder: European and Developing Countries Clinical Trials Partnerships (EDCTP

Coordinator/EDCTP Fellow: Dr Bugwesa Zablon Katale

Call: Career Development Fellowships                   

Start Date Programme: 2020-10-1

End Date: 2023-9-31                                                           

Project Code: TMA2018CDF-2363                        

Status: Active                                           

 

Main objective: To determine the clinical application of whole genome sequencing in the diagnosis of multidrug resistance tuberculosis patients in Tanzania

Objectives:

Primary objective

a) To describe drug susceptibility against first and second line antituberculosis drugs
b) To identify molecular markers associated with drug resistance M. tuberculosis in these population isolates

c) To describe associations between drug resistance genotype and clinical outcome
d) To determine the genetic relatedness of drug resistance M. tuberculosis isolates

 

Work Packages

Work Package 1: Project Management and Capacity building

Work Package 2: Determination of clinical and demographic information from MDRTB and non-MDRTB patients

Work Package 3: Phenotypic drug susceptibility testing and identification of molecular markers associated with drug resistance

Work Package 4: Determination of genetic relatedness and phylogenetic relationship of drug resistance M. tuberculosis isolates

Work Package 5: Determination of the role of genotypic mutation alone or in combination in clinical outcome

Work Package 6: Dissemination, exploitation and communication of research findings at local and international levels

Study design: Unmatched case control study

Host Organization

Tanzania Commission for Science and Technology

 Collaborating Institutions

Kibong’oto Infectious Diseases Hospital

University College of London (UCL)

Muhimbili University of Health and Allied Sciences

Study site: Kibong’oto Infectious Disease Hospital, Kilimanjaro, Tanzania